Phase 3 Readout~month

Phase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap

Name: Phase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap
Start: 2028-06-30

June 30, 2028

Company: GERON CORP (GERN)
Drug: intermediate-2
Indication: Myelofibrosis

Other upcoming events for GERN

Patent ExpiryPatent/Exclusivity Expiry: RYTELO

Jun 16, 2039

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap — GERN Phase 3 Readout | BioSniper